Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    Wavelength-Pharmaceuticals-Insert
    X

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Crescita Therapeutics

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              CANADA Canada

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              CAMBODIA PHAR-MED 2020

              Participation Not Confirmed

              Update your events

              Crescita to Receive One-time Cash Payment Following Amendment to Pliaglis® U.S. Licensing Agreement

              Contact the Supplier

              Lead Product(s): Lidocaine,Tetracaine

              Therapeutic Area: Neurology Product Name: Pliaglis

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Taro Pharmaceutical Industries Ltd.

              Deal Size: Undisclosed Upfront Cash: $3.9 million

              Deal Type: Licensing Agreement July 28, 2020

              Details:

              The Company continues to pursue out-licensing partnerships with focus on approximately 20 countries where Pliaglis has already received regulatory approval.

              IntelGenx

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              CANADA Canada

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              CAMBODIA PHAR-MED 2020

              Participation Not Confirmed

              Update your events

              Intelgenx Announces Adjusted Versafilm® Business Strategy, Next Steps For Rizaport® Versafilm® Program

              Contact the Supplier

              Lead Product(s): Rizatriptan Benzoate

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 06, 2020

              Details:

              IntelGenx recently received from the U.S. FDA Complete Response Letter regarding its resubmitted 505(b)(2) New Drug Application for RIZAPORT® VersaFilm®.

              PharmaCompass__DigitalAd